ArvinasARVN
ARVN
About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Employees: 430
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
315% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $7.41M
57% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 51
40% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 7 (+2) [Q4]
7.91% more ownership
Funds ownership: 103.54% [Q3] → 111.44% (+7.91%) [Q4]
4% less funds holding
Funds holding: 205 [Q3] → 196 (-9) [Q4]
16% less capital invested
Capital invested by funds: $1.75B [Q3] → $1.47B (-$280M) [Q4]
18% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 34
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
25%
upside
Avg. target
$30
213%
upside
High target
$81
742%
upside
13 analyst ratings
9 positive
69%
4 neutral
31%
0 negative
0%
Goldman Sachs Paul Choi 67% 1-year accuracy 10 / 15 met price target | 25%upside $12 | Neutral Maintained | 17 Apr 2025 |
Truist Securities Joon Lee 48% 1-year accuracy 20 / 42 met price target | 118%upside $21 | Buy Maintained | 9 Apr 2025 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target | 742%upside $81 | Buy Reiterated | 7 Apr 2025 |
Morgan Stanley Terence Flynn 50% 1-year accuracy 11 / 22 met price target | 25%upside $12 | Equal-Weight Maintained | 13 Mar 2025 |
Guggenheim Michael Schmidt 43% 1-year accuracy 16 / 37 met price target | 233%upside $32 | Buy Maintained | 13 Mar 2025 |
Financial journalist opinion
Based on 7 articles about ARVN published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m.
Neutral
GlobeNewsWire
2 days ago
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation of ARV-393 combinations in non-Hodgkin lymphoma – NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical combination studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader.
Neutral
GlobeNewsWire
1 week ago
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial –
Neutral
GlobeNewsWire
1 week ago
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies
Negative
Zacks Investment Research
3 weeks ago
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Benzinga
3 weeks ago
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson's disease treatment, ARV-102.
Neutral
GlobeNewsWire
3 weeks ago
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers –
Neutral
GlobeNewsWire
1 month ago
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader – – Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Positive
Zacks Investment Research
1 month ago
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Charts implemented using Lightweight Charts™